ArticleCell2017
Crystal Structure of an LSD-Bound Human Serotonin Receptor.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 240 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 1 pooled it
55.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
240 citing papers in PubMed, 1 synthesis or guideline pooled it, 452 citations in OpenAlex.
- Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.Acta neuropsychiatrica · 2025Pooled it
- LSD increases sleep duration the night after microdosing.Translational psychiatry · 2024Trial
- Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.The international journal of neuropsychopharmacology · 2023Trial
- Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.Addiction biology · 2022Trial
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.Psychopharmacology · 2020Trial
- Sustained antidepressant-like effects of psychedelics through 5-HTNature neuroscience · 2026Article
- Atomic, structural and molecular insights into GPCR ligand binding and signalling.Nature reviews. Molecular cell biology · 2026Review
- LSD reconfigures cortical dynamics through faster brain rhythms and increased fractal dimension.Communications biology · 2026Article
- Mechanistic Basis for 5-HTNature communications · 2026Article
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- Decoding Prolonged Residence Time of 5-HTJournal of chemical information and modeling · 2026Article
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Identification of Subtype-Selective Binding Sites in the Opioid Receptor Family.Journal of chemical information and modeling · 2026Article
- Article
- Allosteric activation of the glutamate receptor mGlu2 by the serotonin receptor 5-HTNature communications · 2026Article
- Investigating the psychedelic hypothesis of kykeon, the sacred elixir of the Eleusinian Mysteries.Scientific reports · 2026Article
- Constitutive activity among orphan G protein-coupled receptors: Molecular mechanisms and pharmacological perspectives.Molecular pharmacology · 2026Review
- Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.Veterinary sciences · 2026Article
- Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026Review
180 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Daniel WackerDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA. Electronic address: dwacker@email.unc.edu.
Sheng WangDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
John D McCorvyDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
Robin M BetzDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA; Biophysics Program, Stanford University, Stanford, CA 94305, USA.
A J VenkatakrishnanDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA.
Anat LevitDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158-2280, USA.
Katherine LansuDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
Zachary L SchoolsDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
Tao CheDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA.
David E NicholsDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158-2280, USA.
Ron O DrorDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA; Biophysics Program, Stanford University, Stanford, CA 94305, USA. Electronic address: ron.dror@stanford.edu.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA; National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA. Electronic address: bryan_roth@med.unc.edu.
University of North Carolina at Chapel Hill · USStanford University · USUniversity of California, San Francisco · USNational Institute of Mental Health · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MScreening CoreU19MH082441 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, MARC G., JIN, JIAN · 2007 to 2016
$15.2MMolecular Biophysics Training Program at StanfordT32GM008294 · NIGMS · STANFORD UNIVERSITY · PI HUANG, KERWYN C. · 1989 to 2019
$7.4MMolecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1MPREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIST32GM007040 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS, ROBERT A · 1985 to 2019
$6.0MTargeting and Trafficking of 5-HT2A Serotonin ReceptorsR01MH061887 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L. · 2000 to 2014
$4.5MDESIGN AND EXPERIMENTAL TESTING OF NEW DOCKING METHODSR01GM059957 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOICHET, BRIAN K · 1999 to 2017
$4.4MOptimizing Lead 5-HT2c Ligands for Use in the Treatment of SchizophreniaR01MH099993 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CALDARONE, BARBARA J., ROTH, BRYAN L. · 2013 to 2016
$2.8MNCI NIH HHS P30 CA016086NIGMS NIH HHS R01 GM059957NIGMS NIH HHS T32 GM007040NIGMS NIH HHS T32 GM008294NIMH NIH HHS R01 MH061887NIMH NIH HHS R01 MH099993NIMH NIH HHS R01 MH112205NIMH NIH HHS U19 MH082441
Abstract
The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal structure of LSD in complex with the human serotonin receptor 5-HT
Indexed as
ArrestinCrystallography, X-RayHumansKineticsLysergic Acid DiethylamideModels, ChemicalMolecular Dynamics SimulationReceptor, Serotonin, 5-HT2BArrestinLysergic Acid DiethylamideReceptor, Serotonin, 5-HT2BcrystallographyGPCRhallucinogensserotonin receptorstructure-function
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.